---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033684"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:28:45.572411+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Liquidia FY2023 net loss $78.5M ($1.21/sh); patent victory clears path for YUTREPIA launch

## Summary
- Net loss $78.5M ($1.21/sh) vs $41.0M ($0.67/sh) in FY2022; R&D spend rose 122% to $43.2M.
- Cash $83.7M at Dec 31, 2023; raised $100M in Jan 2024 via equity placement and debt amendment.
- Federal Circuit denied United Therapeutics' rehearing request, upholding invalidity of '793 Patent; injunction removal awaited.
- YUTREPIA ready for launch in PAH and PH-ILD after Tyvaso exclusivity expires March 31, 2024 and injunction lifted.
- L606 Phase 3 PH-ILD study planned by end-2024; ASCENT enrollment (60 patients) ongoing with interim data expected.

## SEC filing metadata
- accession: 0001104659-24-033684
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/0001104659-24-033684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/tm248678d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033684
- JSON: https://secwatch.observer/filing/0001104659-24-033684.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033684.txt

## Key facts
- Earnings Releases
  Liquidia Corp reported full year ended December 31, 2023 results: revenue $17.5 million.
  - Period: full year ended December 31, 2023
  - Revenue: $17.5 million
  - Result: reported results
  source text: $25.0 million. HCRx has now invested $67.5 million in non-dilutive capital from the $100 million originally contemplated from four tranches under the RIFA. Revenue was $17.5 million for the year ended December 31, 2023, compared with $15.9 million for the year ended December 31, 2022. Revenue related primarily to the sale of Treprostinil Injection under the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/0001104659-24-033684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.